NAD+ (IV/Injection)
Direct intravenous or intramuscular administration of nicotinamide adenine dinucleotide. Rapidly cleared from plasma with half-life ~14 min. IV infusions typically run 250-750 mg over 2-6 hours due to nausea/flushing at faster rates. Directly replenishes cellular NAD+ pools without requiring precursor conversion. Distinct from oral NMN/NR supplementation.
Projected serum levels — 250 mg, weekly
Maintenance schedule: 250 mg weekly (oral).
Modeled steady state after ~7 days: peak ≈ 79.0 mg, trough ≈ 0.000 mg body load. Population-based estimate over 21 days for a 250 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Peptide
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 2.7 h
- Common dose
- 250 mg
- Suggested maximum
- 750 mg/day
- Reference dose range
- 125–750 mg (single dose)
- Suggested cadence
- weekly
Documented interactions
-
moderate
Nicotinamide Riboside (NR, Niagen) + NAD+ (IV/Injection)
NAD+ (IV/Injection) and Nicotinamide Riboside (NR, Niagen) both push the nad salvage pathway and sirt1 in the same direction.
-
moderate
NMN (Nicotinamide Mononucleotide) + NAD+ (IV/Injection)
NAD+ (IV/Injection) and NMN (Nicotinamide Mononucleotide) both push the nad salvage pathway and sirt1 in the same direction.
-
watch
Fisetin + NAD+ (IV/Injection)
Fisetin and NAD+ (IV/Injection) both push the sirt1 in the same direction.
-
watch
Niacin (Vitamin B3) + NAD+ (IV/Injection)
NAD+ (IV/Injection) and Niacin (Vitamin B3) both push the nad salvage pathway in the same direction.
-
watch
Quercetin + NAD+ (IV/Injection)
NAD+ (IV/Injection) and Quercetin both push the sirt1 in the same direction.
-
watch
Resveratrol (trans-Resveratrol) + NAD+ (IV/Injection)
NAD+ (IV/Injection) and Resveratrol (trans-Resveratrol) both push the sirt1 in the same direction.
Serum checks 7 modeled interaction pairings for nad+ (iv/injection) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
First human IV NAD+ pharmacokinetic study showing no change in plasma NAD+ until 2 hours into a 6-hour infusion, with significant increases in NAD+ metabolites (methylnicotinamide, ADPR) in plasma and urine.
-
High-dose intravenous glutathione in man: pharmacokinetics and effects on cyst(e)ine in plasma and urine
Pharmacokinetic study of high-dose IV infusions establishing rapid plasma clearance kinetics relevant to understanding IV delivery of endogenous metabolites including NAD+.
2 published studies referenced in the app, each with a plain-language summary.